PsyBio Therapeutics Initiates Process Development of Proprietary Biosynthetic Norbaeocystin
PsyBio Therapeutics Corp. (TSXV: PSYB) ("PsyBio" or the "Company"), a leader in the field of psychedelic ...
Miami researchers discover process to sustainably produce psilocybin - a drug candidate that could help treat depression
Andrew Jones at Miami University and his team of students may have developed a research first...
RESEARCHERS GENE-HACKED E. COLI TO PRODUCE PSILOCYBIN
Researchers suspect that psilocybin — the psychedelic compound that puts the “magic” in magic mushrooms...
Read More
.png)
Dr. Jones is one of AIChE's 35 Under 35
The American Institute of Chemical Engineers (AIChE) has selected its latest group of engineers for their 35 Under 35 Award, and Dr. J...
PsyBio Therapeutics Announces Retention of Market Maker
PsyBio Therapeutics Corp. (TSXV:PSYB) (“PsyBio” or the “Company”), a leader in the field of psychedelic...
PsyBio Therapeutics Virtually Closes the Market
Evan Levine, Chief Executive Officer, PsyBio Therapeutics Corp. ("PsyBio" or "the Company") (TSXV: PSYB) and his team joined Dani Lipkin, Director, Global Business Development